Published in Am J Physiol Heart Circ Physiol on May 14, 2010
Matrix metalloproteinase-28 deletion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting M2 macrophage activation. Circ Res (2012) 1.94
The myofibroblast matrix: implications for tissue repair and fibrosis. J Pathol (2013) 1.73
Transforming growth factor-beta induces extracellular matrix protein cross-linking lysyl oxidase (LOX) genes in human trabecular meshwork cells. Invest Ophthalmol Vis Sci (2011) 1.60
Systemic sclerosis disease modification clinical trials design: quo vadis? Arthritis Care Res (Hoboken) (2012) 1.39
Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl oxidases in normal liver and early after injury. Am J Physiol Gastrointest Liver Physiol (2013) 1.28
Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature. J Thorac Cardiovasc Surg (2011) 1.06
Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis. Am J Physiol Lung Cell Mol Physiol (2013) 1.02
Tissue mechanics and fibrosis. Biochim Biophys Acta (2013) 0.97
Left and right ventricle late remodeling following myocardial infarction in rats. PLoS One (2013) 0.92
LOXL4 is induced by transforming growth factor β1 through Smad and JunB/Fra2 and contributes to vascular matrix remodeling. Mol Cell Biol (2013) 0.91
Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling. J Mol Cell Cardiol (2015) 0.91
microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int (2014) 0.89
Discovery of undefined protein cross-linking chemistry: a comprehensive methodology utilizing 18O-labeling and mass spectrometry. Anal Chem (2013) 0.87
N-acetyl-seryl-aspartyl-lysyl-proline reduces cardiac collagen cross-linking and inflammation in angiotensin II-induced hypertensive rats. Clin Sci (Lond) (2014) 0.87
The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction. Neth Heart J (2016) 0.86
Molecular pathogenesis of myocardial remodeling and new potential therapeutic targets in chronic heart failure. Ital J Pediatr (2012) 0.85
Cellular mechanisms of tissue fibrosis. 6. Purinergic signaling and response in fibroblasts and tissue fibrosis. Am J Physiol Cell Physiol (2013) 0.83
Discovery and characterization of a photo-oxidative histidine-histidine cross-link in IgG1 antibody utilizing ¹⁸O-labeling and mass spectrometry. Anal Chem (2014) 0.83
Integrated Glycoprotein Immobilization Method for Glycopeptide and Glycan Analysis of Cardiac Hypertrophy. Anal Chem (2015) 0.81
Left ventricular remodeling: one small step for the extracellular matrix will translate to a giant leap for the myocardium. Congest Heart Fail (2013) 0.80
Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies. Clin Gastroenterol Hepatol (2013) 0.80
The Living Scar - Cardiac Fibroblasts and the Injured Heart. Trends Mol Med (2016) 0.80
Building a better infarct: Modulation of collagen cross-linking to increase infarct stiffness and reduce left ventricular dilation post-myocardial infarction. J Mol Cell Cardiol (2015) 0.78
Featured Article: Cardioprotective effects of lysyl oxidase inhibition against volume overload-induced extracellular matrix remodeling. Exp Biol Med (Maywood) (2015) 0.78
Matrix metalloproteinase (MMP)-19-deficient fibroblasts display a profibrotic phenotype. Am J Physiol Lung Cell Mol Physiol (2015) 0.77
Copper sulfate affects Nile tilapia (Oreochromis niloticus) cardiomyocytes structure and contractile function. Ecotoxicology (2011) 0.76
Apocynin influence on oxidative stress and cardiac remodeling of spontaneously hypertensive rats with diabetes mellitus. Cardiovasc Diabetol (2016) 0.75
MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure. Sci Rep (2017) 0.75
TGF-β1 Pretreatment Improves the Function of Mesenchymal Stem Cells in the Wound Bed. Front Cell Dev Biol (2017) 0.75
Biomechanics of Cardiac Function. Compr Physiol (2015) 0.75
Action of SNAIL1 in Cardiac Myofibroblasts Is Important for Cardiac Fibrosis following Hypoxic Injury. PLoS One (2016) 0.75
Simultaneously Targeting Myofibroblast Contractility and Extracellular Matrix Cross-Linking as a Therapeutic Concept in Airway Fibrosis. Am J Transplant (2016) 0.75
Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). Am J Cardiol (2015) 0.75
Targeted inhibition of Focal Adhesion Kinase Attenuates Cardiac Fibrosis and Preserves Heart Function in Adverse Cardiac Remodeling. Sci Rep (2017) 0.75
Excess Linoleic Acid Increases Collagen I/III Ratio and "Stiffens" the Heart Muscle Following High Fat Diets. J Biol Chem (2015) 0.75
Increased serum lysyl oxidase-like 2 levels correlate with the degree of left atrial fibrosis in patients with atrial fibrillation. Biosci Rep (2017) 0.75
Crohn's Strictures-Moving Away from the Knife. Front Pediatr (2017) 0.75
Periodontal-induced chronic inflammation triggers macrophage secretion of Ccl12 to inhibit fibroblast-mediated cardiac wound healing. JCI Insight (2017) 0.75
Downregulation of Lysyl Oxidase Protects Retinal Endothelial Cells From High Glucose-Induced Apoptosis. Invest Ophthalmol Vis Sci (2017) 0.75
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int (2011) 3.48
Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med (2010) 3.42
Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation (2002) 2.41
C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol (2006) 2.20
Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension. Hypertension (2007) 2.17
Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Fail (2009) 2.03
Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol (2006) 2.03
Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation (2004) 1.81
Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension (2010) 1.64
Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: potential clinical implications in hypertension. Hypertension (2009) 1.63
Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation (2010) 1.62
Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. J Hypertens (2004) 1.58
Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Hypertens (2007) 1.58
Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure. J Hypertens (2007) 1.57
Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. J Hypertens (2005) 1.53
Preventing ventricular dysfunction in pacemaker patients without advanced heart failure: results from a multicentre international randomized trial (PREVENT-HF). Eur J Heart Fail (2011) 1.50
Upregulation of myocardial Annexin A5 in hypertensive heart disease: association with systolic dysfunction. Eur Heart J (2007) 1.47
Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients. J Hypertens (2013) 1.47
Insulin resistance determines phagocytic nicotinamide adenine dinucleotide phosphate oxidase overactivation in metabolic syndrome patients. J Hypertens (2009) 1.42
Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. Kidney Int (2010) 1.41
[Characteristics of hypertensive cardiomyopathy in a population of hypertensive patients never treated]. Med Clin (Barc) (2005) 1.40
[Association of age, inflammatory markers and subclinical atherosclerosis in subjects free from cardiovascular disease]. Med Clin (Barc) (2008) 1.40
[Effect of statin treatment begun early after acute myocardial infarction on endothelial function in patients with normal levels of cholesterol. VAATOPE Study (VAlue of ATOrvastatin in Postinfarction Endothelium)]. Med Clin (Barc) (2006) 1.39
Surrogate markers for cardiovascular disease: structural markers. Circulation (2004) 1.36
T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging (2013) 1.35
Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail (2002) 1.35
Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nat Clin Pract Cardiovasc Med (2005) 1.34
G protein-coupled receptor kinase 2 plays a relevant role in insulin resistance and obesity. Diabetes (2010) 1.32
Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol (2004) 1.21
A midzone-based ruler adjusts chromosome compaction to anaphase spindle length. Science (2011) 1.19
New targets to treat the structural remodeling of the myocardium. J Am Coll Cardiol (2011) 1.17
Oxidative stress and vascular remodelling. Exp Physiol (2005) 1.17
The inhibitory effect of leptin on angiotensin II-induced vasoconstriction in vascular smooth muscle cells is mediated via a nitric oxide-dependent mechanism. Endocrinology (2006) 1.16
AT1 receptor antagonism attenuates target organ effects of salt excess in SHRs without affecting pressure. Am J Physiol Heart Circ Physiol (2007) 1.15
Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol (2007) 1.14
Fibrosis in hypertensive heart disease: role of the renin-angiotensin-aldosterone system. Med Clin North Am (2004) 1.14
Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. Circ Heart Fail (2013) 1.14
The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. J Hypertens (2005) 1.13
Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. Am J Physiol Endocrinol Metab (2007) 1.11
Cardiomyocyte apoptosis in hypertensive cardiomyopathy. Cardiovasc Res (2003) 1.10
Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease? J Mol Cell Cardiol (2002) 1.08
NADPH oxidase CYBA polymorphisms, oxidative stress and cardiovascular diseases. Clin Sci (Lond) (2008) 1.07
A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc Res (2008) 1.07
Prevalence of left ventricular diastolic dysfunction in European populations based on cross-validated diagnostic thresholds. Cardiovasc Ultrasound (2012) 1.06
GLP-1 and cardioprotection: from bench to bedside. Cardiovasc Res (2012) 1.06
Pregnancy outcome in patients treated with cervical conization for cervical intraepithelial neoplasia. Int J Gynaecol Obstet (2011) 1.05
Telomere dysfunction in hypertension. J Hypertens (2007) 1.04
Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase. Hypertension (2012) 1.04
Phagocytic NADPH oxidase overactivity underlies oxidative stress in metabolic syndrome. Diabetes (2006) 1.03
Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension (2008) 1.02
Myocardial fibrosis, impaired coronary hemodynamics, and biventricular dysfunction in salt-loaded SHR. Am J Physiol Heart Circ Physiol (2005) 1.02
Association between left ventricular mass and telomere length in a population study. Am J Epidemiol (2010) 1.02
Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction. Hypertension (2012) 0.99
Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis. Curr Opin Nephrol Hypertens (2004) 0.98
Cardiac resynchronization therapy-induced left ventricular reverse remodelling is associated with reduced plasma annexin A5. Cardiovasc Res (2010) 0.97
Phagocytic NADPH oxidase-dependent superoxide production stimulates matrix metalloproteinase-9: implications for human atherosclerosis. Arterioscler Thromb Vasc Biol (2006) 0.96
Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am J Physiol Heart Circ Physiol (2011) 0.96
The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension. J Hypertens (2006) 0.95
Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: potential diagnostic implications. J Hypertens (2009) 0.95
Molecular mechanisms of atherosclerosis in metabolic syndrome: role of reduced IRS2-dependent signaling. Arterioscler Thromb Vasc Biol (2008) 0.95
microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-β1 up-regulation. Clin Sci (Lond) (2014) 0.94
NADPH oxidase-mediated oxidative stress: genetic studies of the p22(phox) gene in hypertension. Antioxid Redox Signal (2005) 0.94
Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase? Cardiovasc Res (2013) 0.94
The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus. Cardiovasc Diabetol (2013) 0.93
Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arterioscler Thromb Vasc Biol (2006) 0.93
Hypertensive left ventricular hypertrophy risk: beyond adaptive cardiomyocytic hypertrophy. J Hypertens (2011) 0.93
Leptin inhibits angiotensin II-induced intracellular calcium increase and vasoconstriction in the rat aorta. Endocrinology (2002) 0.93
Biological processes, properties and molecular wiring diagrams of candidate low-penetrance breast cancer susceptibility genes. BMC Med Genomics (2008) 0.92
Preliminary characterisation of the promoter of the human p22(phox) gene: identification of a new polymorphism associated with hypertension. FEBS Lett (2003) 0.92
Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J Hypertens (2005) 0.91
Biochemical markers of myocardial remodelling in hypertensive heart disease. Cardiovasc Res (2008) 0.91
Oxidative stress and atherosclerosis in early chronic kidney disease. Nephrol Dial Transplant (2006) 0.90